*Paediatric Neurology, Auckland District Health Board, Auckland, New Zealand;
†Department of Neurosciences, Rady Children's Hospital San Diego, University of California, San Diego, California;
‡Department of Neurosciences, University of California, San Diego, California;
Departments of §Neonatology and
‖Pediatric Neurology, UCSF Benioff Children's Hospital, San Francisco, California;
¶Department of Pediatrics, Rady Children Hospital San Diego, University of California, San Diego, California;
#Division of Neonatology, Rady Children's Hospital, San Diego, California;
**School of Nursing, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand;
††Neonatology, Auckland District Health Board, Auckland, New Zealand;
‡‡Division of Neonatology, Department of Pediatrics, University of California, San Diego, California;
§§San Diego Neonatology Inc, Sharp Mary Birch Hospital for Women and Newborns, San Diego, California;
‖‖Neonatal Research Institute, Sharp Mary Birch Hospital for Women and Newborns, San Diego, California;
¶¶Department of Neurosciences, Sharp Mary Birch Hospital for Women and Newborns, University of California, San Diego; and
##Departments of Pediatrics and Neurosciences, Rady Children's Hospital San Diego, University of California, San Diego, California.
Address correspondence and reprint requests to Cynthia Sharpe, MBChB, Paediatric Neurology, Starship Children's Hospital, Park Road, Private Bag 92-024, Auckland 1142, New Zealand; e-mail: [email protected].
The authors have no funding or conflicts of interest to disclose.
The Persyst EEG software company has worked closely with the authors on the NEOLEV2 study and has provided their software to the researchers free of charge but has had no input into this feasibility study or this manuscript. The Corticare commercial EEG monitoring company has worked closely with the authors on the NEOLEV2 study on a commercial basis. This company has had no input into the writing of this manuscript. This manuscript discusses use of the automated neonatal seizure detection algorithm created by the Persyst EEG software company, which is not yet FDA-approved for commercial use.
The NEOLEV2 study was funded by the FDA 1 RO1FD004147-01A1.
Presented as an abstract at the Pediatric Academic Society Meeting, San Francisco, May 10, 2017.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.clinicalneurophys.com).
